Studies Link Actos to Bladder Cancer
Actos is a drug used to treat Type II diabetes. It was approved for use in the U.S. by the FDA in 1999. Recent studies, however, show that long-term use of Actos can lead to multiple health problems. Actos is manufactured by the Japanese pharmaceutical company, Takeda Pharmaceuticals. Takeda is one of the top 15 pharmaceutical companies in the world, thanks largely due to their best-selling drug, Actos. Since its launch in 1999, Actos has become the top drug for the treatment of type II diabetes with sales of over $4 billion annually.
Actos acts by increasing the sensitivity of cells to insulin, thus allowing for more effective removal of glucose from these cells and thereby controlling the blood sugar. In other words, Actos works by manipulating the DNA of certain genes to increase their uptake of insulin. These genetic manipulations can cause mutations in DNA, which can in turn lead to formation of cancer cells. Actos also produces toxins that are stored in the bladder before it is expelled further increasing the risk of developing bladder cancer.
Several studies have linked Actos with an increased risk of developing bladder cancer. In 2011, the FDA announced that data collected from a 10-year study showed that taking Actos for more than a year increased the likelihood of developing bladder cancer by 40%. The study included data collected from over 190,000 patients from 1997 to 2008. This led the FDA to issue a public warning of the drug’s side effects and they also ordered the manufacturer to include the same warning on its label. In July 2012, the Canadian Medical Association Journal published research involving over 2,000,000 patients which showed a 22% increased risk of developing bladder cancer with long-term Actos use. The same year, another study, published by the British Medical Journal, involving more than 100,000 patients showed that taking Actos for more than two years doubled the chances of developing bladder cancer. A study in France involving 1.5 million patients also showed a statistically significant increase in the risk of developing bladder cancer in patients taking Actos. This study led the French and German government to suspend sales of Actos. In the U.S. however, Actos still remains on the market.
Actos has also additionally been linked to other side effects such as congestive heart failure, heart attacks, and bone fractures. More than a million type II diabetes patients have been prescribed Actos and if the drug continues on the market, many more will be. If you or any of your loved ones have been harmed by taking Actos, you can help stop this menace by filing a lawsuit against the makers of this drug. Not only will you warn others about the dangers of this drug, you can also obtain compensation for medical expenses and other losses incurred. Contact one of our Indiana defective drug attorneys now and we will give you a free evaluation of your case. We promise we will not collect any fees until we obtain compensation for you first.